Literature DB >> 7704504

Three-dimensional conformal radiotherapy in bronchogenic carcinoma: considerations for implementation.

B Emami1, M V Graham, J A Purdy.   

Abstract

Lung cancer continues to be a major health problem worldwide. In spite of significant technological and scientific medical progress, the final outcome of this disease is still dismal. Except for a small percentage of patients with early stage who undergo complete surgical resection, local control continues to be disappointingly low. In a recent report by Arriagada et al. (Arriagada R, Le Chevalier T, Quoix E, Rufie P, de Cremoux H, Douillard J-Y, Tarayre M, Pignon, J-P, LaPlanche, A. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991; 20:1183-1190), biopsy proven local control by RT alone was only 17%. This team also found that the addition of combination chemotherapy, although it has decreased distant metastasis, has not had any impact on local control. There are some indications in the literature to suggest that higher doses of radiation to the target volume (tumor) may result in improved local control in inoperable non-small cell lung cancer. This temptation for increasing dose to target volume, however, should not result in inappropriate normal tissue side-effects and complications. Three-dimensional (3D) conformal radiation therapy has shown a significant potential for improving radiation treatment planning in several sites, both for tumor coverage and sparing normal tissue. Using this technology, progress in uncomplicated locoregional control of lung cancer may become a reality. The following is a review of literature and analysis of the currently available information on this subject.

Entities:  

Mesh:

Year:  1994        PMID: 7704504     DOI: 10.1016/0169-5002(94)91872-4

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  2 in total

1.  Radiotherapy Planning Complexity and Survival after Treatment of Advanced Stage Lung Cancer in the Elderly.

Authors:  Benjamin Goldsmith; Jamie Cesaretti; Juan P Wisnivesky
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

Review 2.  Non-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand?

Authors:  R L Eakin; M I Saunders
Journal:  Ulster Med J       Date:  2000-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.